EUVIMEDEUVIMED entdecken
Crossref

Novel [ 68 Ga/ 177 Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy

Ran Wang, Wenbin Jin, Yang Luo, Haiyan Hong iD, Ruiyue Zhao, Linlin Li, Li Yan, Jinping Qiao, Karl Ploessl iD, Lin Zhu, Hank F Kung iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Ran Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Gallium Radioisotopes, Lutetium, Antigens, Surface. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) overexpressed in prostate cancer cells can serve as a target for imaging and radioligand therapy (RLT). Previously, [68Ga]Ga-P16-093, containing a Ga(III) chelator, N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC), displayed excellent PSMA-targeting properties and showed a high tumor uptake and retention useful for diagnosis in prostate cancer patients. Recently, [177Lu]Lu-PSMA-617 has been approved by the U.S. food and drug administration (FDA) for the treatment of prostate cancer patients. Derivatives of PSMA-093 using AAZTA (6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid), as the chelator, were designed as alternative agents forming complexes with both diagnostic and therapeutic radiometals, such as gallium-68 (log K = 22.18) or lutetium-177 (log K = 21.85). The aim of this study is to evaluate AAZTA-Gly-O-(methylcarboxy)-Tyr-Phe-Lys-NH-CO-NH-Glu (designated as AZ-093, 1) leading to a gallium-68/lutetium-177 theranostic pair as potential PSMA targeting agents. Synthesis of the desired precursor, AZ-093, 1, was effectively accomplished. Labeling with either [68Ga]GaCl3 or [177Lu]LuCl3 in a sodium acetate buffer solution (pH 4-5) at 50 °C in 5 to 15 min produced either [68Ga]Ga-1 or [177Lu]Lu-1 with high yields and excellent radiochemical purities. Results of in vitro binding studies, cell uptake, and retention (using PSMA-positive prostate carcinoma cells line, 22Rv1-FOLH1-oe) were comparable to that of [68Ga]Ga-P16-093 and [177Lu]Lu-PSMA-617, respectively. Specific cellular uptake was determined with or without the competitive blocking agent (2 μM of "cold" PSMA-11). Cellular binding and internalization showed a time-dependent increase over 2 h at 37 °C in the PSMA-positive cells. The cell uptakes were completely blocked by the "cold" PSMA-11 suggesting that they are competing for the same PSMA binding sites. In the mouse model with implanted PSMA-positive tumor cells, both [68Ga]Ga-1 and [177Lu]Lu-1 displayed excellent uptake and retention in the tumor. Results indicate that [68Ga]Ga/[177Lu]Lu-1 (68Ga]Ga/[177Lu]Lu-AZ-093) is potentially useful as PSMA-targeting agent for both diagnosis and radiotherapy of prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGallium RadioisotopesLutetiumAntigens, SurfaceRadiopharmaceuticalsGlutamate Carboxypeptidase IIMaleHumansCell Line, TumorRadioisotopesAnimalsChelating AgentsProstate-Specific AntigenTissue DistributionMiceEdetic AcidPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

chelating agentsdiagnosisligand bindingprostate cancerradioligand therapy

Substanzen

Gallium RadioisotopesLutetiumAntigens, SurfaceRadiopharmaceuticalsGlutamate Carboxypeptidase IIFOLH1 protein, humanLutetium-177RadioisotopesGallium-68Chelating Agents

Autor:innen und Institutionen

  • Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.
  • Department of Nuclear Medicine, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.
  • Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518000, China.
  • Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
  • Five Eleven Pharma Inc., Philadelphia, Pennsylvania 19104, United States.

ORCID-Profile: Haiyan Hong, Karl Ploessl, Hank F Kung

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, R., Jin, W., Luo, Y., Hong, H., Zhao, R., Li, L., Yan, L., Qiao, J., Ploessl, K., Zhu, L., & Kung, H. F. (2024). Novel [ 68 Ga/ 177 Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00020

Vancouver

Wang R, Jin W, Luo Y, Hong H, Zhao R, Li L, et al. Novel [ 68 Ga/ 177 Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00020

BibTeX
@article{Wang2024,
  author = {Wang, Ran and Jin, Wenbin and Luo, Yang and Hong, Haiyan and Zhao, Ruiyue and Li, Linlin and Yan, Li and Qiao, Jinping and Ploessl, Karl and Zhu, Lin and Kung, Hank F},
  title = {Novel [ 68 Ga/ 177 Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00020}
}
Kostenlos starten →